ReviewJournal of clinical laboratory analysis2026
Lipid Metabolism, Lipogenesis, and Resistance to Third Generation EGFR-TKIs.
Review in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCancer metabolism has emerged as a critical area of study in cancer research. Dysregulated lipid metabolism has been observed in various cancer types, and this metabolic rewiring facilitates tumor growth, metastasis, and treatment resistance. Additionally, aberrant lipid metabolism is associated with poor patient prognosis.
methodsThis review aims to provide a comprehensive overview of cancer metabolism, with a specific focus on lipid metabolism/lipogenesis and its association with resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
resultsLipid metabolism/lipogenesis provides cancer cells with energy substrates and building blocks for membrane biogenesis. In parallel, resistance to third-generation EGFR-TKIs has emerged as a major challenge in the treatment of non-small cell lung cancer (NSCLC) driven by EGFR mutations.
conclusionUnderstanding the intricate connections between lipid metabolism/lipogenesis and resistance to third-generation EGFR-TKIs is crucial for developing effective therapeutic strategies. Targeting lipid metabolism pathways holds promise as a novel therapeutic approach to overcome treatment resistance and improve patient prognosis. Further research is needed to better understand the underlying mechanisms and identify potential drug targets in lipid metabolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.